Study of BMS-833923 in Two Specific Patients With Basal Cell Nevus Syndrome

Summary

This is an extension study of Protocol CA194002 to allow 2 specific participants with basal cell nevus syndrome in the CA194002 study at Princess Margaret Cancer Centre who are still benefitting from the study drug BMS-833923 to continue receiving the study drug. This study will continue to evaluate the safety and tolerability of BMS-833923 in these participants.

Timeline

Start

2014-02

Primary completion

2017-05

Completion

2017-05

Drugs

Indications